68Ga-DOTATATE PET/CT上的心脏神经内分泌肿瘤转移:识别与预后意义
回顾性分析490例连续患者的68Ga-DOTATATE PET/CT,270例转移性NET中9例(3.3%)存在心脏转移,均为1-2级胃肠胰NET,最常见源于小肠。心脏转移组与140例无心脏转移对照相比,心血管不良事件风险(P=0.91)和死亡风险(P=0.83)均无显著差异。心脏转移灶DOTATATE摄取显著高于11例活动性心脏结节病患者的局灶性心肌炎症摄取。
要点
- 常规68Ga-DOTATATE PET/CT可在3%的转移性NET患者中识别心脏转移。
- 心脏NET转移不增加心血管事件或死亡风险。
- 心脏转移灶DOTATATE摄取显著高于心脏结节病心肌炎症,可作为鉴别特征。
核心结论
- 常规68Ga-DOTATATE PET/CT可用于识别约3%转移性NET患者中的心脏转移。
- 心脏NET转移不增加额外的心血管事件风险或死亡风险。
- 与局灶性心肌炎症相比,心脏NET转移的DOTATATE摄取程度高,为其鉴别特征。
研究设计与样本
- 单中心回顾性研究,连续纳入490例患者的68Ga-DOTATATE PET/CT,回顾判读转移部位。
- 共识别270例转移性NET患者,其中9例(3.3%)有心脏转移;对照组为140例无心脏转移的1-2级胃肠胰转移性NET患者。
- 另与11例因研究目的行68Ga-DOTATATE PET/CT的活动性心脏结节病患者比较心脏摄取。
主要发现
- 9例心脏NET转移患者均为1-2级胃肠胰NET,最常见来自小肠(7例)。
- Kaplan-Meier分析显示,有无心脏转移的转移性NET患者心血管不良事件风险无显著差异(log-rank检验P=0.91),死亡风险亦无显著差异(P=0.83)。
- 心脏NET转移组心脏SUVmax显著高于心脏结节病组(P=0.027),SUVmax与心肌本底比值亦显著高于心脏结节病组(P=0.021),两组无重叠。
关键数值与推荐
- 心脏NET转移的患病率为3.3%(9/270例转移性NET患者)。
- 心血管不良事件风险比较log-rank检验P=0.91,死亡风险比较P=0.83。
- 心脏SUVmax组间比较P=0.027,SUVmax与心肌本底比值组间比较P=0.021。
临床怎么用
- 常规68Ga-DOTATATE PET/CT可用于识别转移性NET患者中的心脏转移。
- 心脏NET转移本身不 confer 额外心血管或死亡风险。
- 心脏病灶DOTATATE高摄取有助于与局灶性心肌炎症鉴别。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Neuroendocrine tumor (NET) metastases to the heart are found in 1%-4% of NET patients and have been reported primarily in the form of individual cases. We investigated the prevalence, clinical characteristics, imaging features, and outcomes of NET patients with cardiac metastases on 68Ga-DOTATATE PET/CT. Methods: 68Ga-DOTATATE PET/CT of 490 consecutive patients from a single institution were retrospectively reviewed for sites of metastases. The cumulative cardiovascular event rate and overall survival of patients with cardiac NET metastases (CNMs) were compared with those of a control group of metastatic NET patients without cardiac metastases. In patients with CNMs, the cardiac SUVmax with and without normalization to the myocardial background uptake was compared with a separate cohort of 11 patients with active cardiac sarcoidosis who underwent 68Ga-DOTATATE PET/CT for research purposes. Results: In total, 270 patients with metastatic NETs were identified, 9 (3.3%) of whom had CNMs. All 9 patients had grade 1-2 gastroenteropancreatic NETs, most commonly from the small intestine (7 patients). The control group consisted of 140 patients with metastatic grade 1-2 gastroenteropancreatic NETs. On Kaplan-Meier analysis, there was no significant difference in the risk of cardiovascular adverse events (P = 0.91 on log-rank test) or mortality (P = 0.83) between the metastatic NET patients with and without cardiac metastases. The degree of cardiac DOTATATE uptake was significantly higher in CNMs than in patients with cardiac sarcoidosis without overlap, in terms of both cardiac SUVmax (P = 0.027) and SUVmax-to-myocardial background ratio (P = 0.021). Conclusion: Routine 68Ga-DOTATATE PET/CT can be used to identify CNMs in 3% of patients with metastatic NETs. CNMs do not confer added cardiovascular or mortality risk. A distinguishing feature of CNMs is their high degree of DOTATATE uptake compared with focal myocardial inflammation.
引用
- Lee H, Alhamshari AS, Patel V, et al. Cardiac Neuroendocrine Tumor Metastases on 68Ga-DOTATATE PET/CT: Identification and Prognostic Significance. J Nucl Med. 2024. PMID: 39362763. doi:10.2967/jnumed.124.267948
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。